China's innovative drug outbound business development (BD) has achieved another milestone breakthrough! On January 30, CSPC PHARMA announced it has entered into a strategic R&D collaboration and licensing agreement with global biopharmaceutical leader AstraZeneca. The partnership aims to leverage the group's proprietary sustained-release drug delivery technology platform and AI-driven peptide drug discovery platform to develop innovative long-acting peptide drugs. Should all subsequent R&D and sales milestones be successfully met, CSPC PHARMA is entitled to receive payments totaling up to $18.5 billion.
According to incomplete statistics, this transaction sets a new record for the highest total value in a BD deal by a Chinese pharmaceutical company, surpassing the previous $13 billion transaction between Kintor Pharmaceutical and Biohaven & AimedBio. Its $1.2 billion upfront payment is second only to the amount previously agreed between 3SBio and Pfizer for their PD-1/VEGF collaboration.
However, the secondary market reaction was unfavorable. CSPC PHARMA's stock opened higher but then trended lower, plummeting nearly 13% intraday before closing down 10.2%. What are the reasons? Analysts suggest it may be the result of multiple overlapping factors.
Judging from CSPC PHARMA's recent stock performance, the market may have priced in the news in advance. Prior to the agreement announcement, CSPC PHARMA's stock had experienced several consecutive days of strong gains, with a particularly sharp single-day increase of 6.14% on January 28, reaching a new annual high. Following the announcement, some investors likely chose to take profits, creating selling pressure characteristic of a "good news realization" scenario.
From the perspective of earnings contribution, although the total agreement value reaches $18.5 billion, the upfront payment is only $1.2 billion. The remaining $17.3 billion consists of R&D and sales milestone payments, which will only materialize over several years upon successful progression through multiple clinical stages, offering limited short-term cash flow contribution.
Broader market and sector-wide adjustments also played a role. On January 30, Hong Kong stocks underwent a significant correction, with the Hang Seng Index, Hang Seng Tech Index, and Hang Seng Biotechnology Index all falling over 2%. The Hong Kong Stock Connect innovative drug sector followed the market downward, with leading companies like Sino Biopharmaceutical, BeiGene, and 3SBio collectively declining. The Hong Kong Stock Connect Innovative Drug ETF (520880) closed down 2.45%.
Shifting market sentiment has intensified volatility within the Hong Kong Stock Connect innovative drug sector. However, judging by the Hong Kong Stock Connect Innovative Drug ETF's (520880) substantial premium throughout the trading day, significant capital may still be accumulating positions during the dip. Over the preceding 10 days, fund 520880 accumulated over 274 million yuan in net subscriptions.
The core logic for domestic innovative drugs remains robust, potentially presenting a favorable window for strategic positioning. Western Securities points out that accelerating BD outbound activities, the convergence of innovative drug pricing between China and the US, and the narrowing market capitalization gap among innovative drug companies collectively suggest substantial medium-to-long-term growth potential.
For positioning in core innovative drug assets at lower levels, consider the high-flexibility T+0 tool—the Hong Kong Stock Connect Innovative Drug ETF (520880) and its corresponding feeder fund (025221). The underlying index (Hang Seng Hong Kong Stock Connect Innovative Drug Select Index) possesses three distinct advantages, highlighting its prominent allocation value: 1. 100% Purity. Excludes CXO companies, focusing purely on innovative drugs, and provides comprehensive coverage of innovative drug R&D companies. 2. High Concentration of Leaders. The top ten innovative drug leaders account for over 73% of the index weight, representing the core strength of the innovative drug sector. 3. Controlled Risk. Imposes mandatory weight reductions on components with poorer liquidity, effectively managing tail risks.
Interested in also capturing opportunities in A-share innovative drugs? Consider the only on-exchange ETF tracking the pharmaceutical index—the Pharmaceutical ETF (562050) and its feeder fund (024986). It aggregates the top 50 A-share pharmaceutical leaders, with an innovative drug allocation exceeding 60%, while also incorporating high-dividend traditional Chinese medicine leaders, offering both growth potential and notable resilience.
*Source: Western Securities Report dated 20260112. Data Source: Shanghai, Shenzhen, and Hong Kong Stock Exchanges, public information. Fund fee details are available in the respective fund legal documents.
Risk Disclosure: Index constituents mentioned are for illustrative purposes only; descriptions of individual stocks do not constitute investment advice in any form nor represent the holdings or trading动向 of any fund managed by the manager. The fund manager assesses the risk rating of the Hong Kong Stock Connect Innovative Drug ETF and its feeder fund as R4 - Medium-High Risk, suitable for Aggressive (C4) and above investors. The risk rating of the Pharmaceutical ETF and its feeder fund is assessed as R3 - Medium Risk, suitable for Balanced (C3) and above investors. Any information appearing in this article is for reference only, and investors are responsible for any independent investment decisions. Furthermore, any views, analysis, or forecasts herein do not constitute investment advice to readers and shall not be liable for any direct or indirect losses resulting from the use of this content. The performance of other funds managed by the fund manager does not guarantee the performance of this fund. Past performance of a fund is not indicative of its future performance. Fund investment carries risks; invest cautiously.
MACD golden cross signals have formed, and these stocks are performing well!
Comments